New! Sign up for our free email newsletter.
Science News
from research organizations

Toward a resistance-proof antiviral that can treat many diseases

Date:
April 20, 2016
Source:
American Chemical Society
Summary:
Scientists and health officials are marshalling forces to fight Zika, the latest in a string of recent outbreaks. Many of these efforts target that virus specifically, but some researchers are looking for a broader approach. Now one team reports a new strategy to fight a wide range of viruses that appears to be safe in vivo and could evade a virus's ability to develop resistance.
Share:
FULL STORY

Scientists and health officials are marshalling forces to fight Zika, the latest in a string of recent outbreaks. Many of these efforts target that virus specifically, but some researchers are looking for a broader approach. Now one team reports in ACS' journal Macromolecules a new strategy to fight a wide range of viruses that appears to be safe in vivo and could evade a virus's ability to develop resistance.

Viruses are wily foes. They come in different forms, mutate rapidly and develop resistance to drugs easily. To fight them, scientists have largely attempted to tackle them one by one. But there are still no treatments for many viral infections, such as dengue and Ebola, even though some have been around for decades. A new approach aims to act more broadly against multiple viruses and involves targeting both viral surfaces and human cells. This strategy could also stop the pathogens in a way that could avoid the development of resistance. But so far, these methods have been toxic to healthy mammalian cells. Yi Yan Yang, Naoki Yamamoto, James Hedrick and colleagues wanted to find a safer method.

The researchers started with a polymer, called polyethylenimine (PEI), that had prevented viral infection through electrostatic interactions in previous studies. The PEI in those studies, however, was toxic to cells. So Yang and her collaborators modified it with mannose, a kind of sugar. The resulting complex interacted with the surfaces of both viral and human cells, and thus blocked the viruses from infecting the cells in lab testing. The researchers say this interaction can happen regardless of mutations and would make it difficult for a pathogen to sidestep. After two weeks of testing in an animal model, the modified PEI showed no toxic effects.

The authors acknowledge funding from the Institute of Bioengineering and Nanotechnology, the National University of Singapore and the IBM Almaden Research Center.


Story Source:

Materials provided by American Chemical Society. Note: Content may be edited for style and length.


Journal Reference:

  1. Koji Ichiyama, Chuan Yang, Lakshmi Chandrasekaran, Shaoqiong Liu, Lijun Rong, Yue Zhao, Shujun Gao, Ashlynn Lee, Kenji Ohba, Youichi Suzuki, Yoshiyuki Yoshinaka, Kunitada Shimotohno, Kei Miyakawa, Akihide Ryo, James Hedrick, Naoki Yamamoto, Yi Yan Yang. Cooperative Orthogonal Macromolecular Assemblies with Broad Spectrum Antiviral Activity, High Selectivity, and Resistance Mitigation. Macromolecules, 2016; 49 (7): 2618 DOI: 10.1021/acs.macromol.6b00091

Cite This Page:

American Chemical Society. "Toward a resistance-proof antiviral that can treat many diseases." ScienceDaily. ScienceDaily, 20 April 2016. <www.sciencedaily.com/releases/2016/04/160420104158.htm>.
American Chemical Society. (2016, April 20). Toward a resistance-proof antiviral that can treat many diseases. ScienceDaily. Retrieved April 19, 2024 from www.sciencedaily.com/releases/2016/04/160420104158.htm
American Chemical Society. "Toward a resistance-proof antiviral that can treat many diseases." ScienceDaily. www.sciencedaily.com/releases/2016/04/160420104158.htm (accessed April 19, 2024).

Explore More

from ScienceDaily

RELATED STORIES